
    
      Multi centre, prospective, non interventional study in 200-240 UK relapsing remitting
      multiple sclerosis patients assessing the change in QoL and PRO outcome measures from
      baseline to 12 months after starting fingolimod. Patients will complete 4 questionnaires at
      baseline (prior to first fingolimod dose), then repeat them at 3, 6 and 12 month intervals
      via post.
    
  